Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition

PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRAS(G12C) mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathwa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Ryan, Meagan B., de la Cruz, Ferran Fece, Phat, Sarah, Myers, David T., Wong, Edmond, Shahzade, Heather A., Hong, Catriona B., Corcoran, Ryan B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124991/
https://ncbi.nlm.nih.gov/pubmed/31776128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3523
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak